Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on April 15, 2025
CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions
GlobeNewswire
·
April 15, 2025
The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemes The trial is expected to enroll 250 patients to receive treatment over 36 weeks BERKELEY HEIGHTS, N.J., April 15, 2025 (GLOBE NEWSWIRE …
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
GlobeNewswire
·
April 15, 2025
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext …
Galapagos kondigt het vertrek van haar CFO en COO, Thad Huston, aan per 1 augustus 2025
GlobeNewswire
·
April 15, 2025
Mechelen, België; 15 april 2025, 07:30 CET; gereglementeerde informatie - voorwetenschap – Galapagos NV (Euronext …
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
GlobeNewswire
·
April 15, 2025
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in …
Communiqué de presse : Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO
GlobeNewswire
·
April 15, 2025
Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO De nouvelles données de phase II démontrent l’efficacité de l’amlitélimab dans le …
Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025
GlobeNewswire
·
April 15, 2025
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial …
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
GlobeNewswire
·
April 15, 2025
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of …